

## **RESPONSE**

### **A. Status of the Claims**

Claims 38-60 were pending at the time of the Restriction Requirement, with claims 1-37 having been canceled in the Preliminary Amendment filed with the application. Claims 55-60 are withdrawn from consideration at this time in view of the election of the Group I invention made below in response to the Restriction Requirement. Therefore, claims 38-54 are presently under consideration in the case.

### **B. Response to Restriction Requirement**

In response to the restriction requirement, Applicants elect, *without traverse*, to prosecute the Group I invention, as exemplified by claims 38-54, drawn to a hyper-immune serum reactive antigen and a pharmaceutical composition. Applicants further elect SEQ ID NO:32 as the sequence for prosecution.

### **C. Response to Species Election Requirement**


The examiner has also entered a species election requirement with regard to claim 50. Applicants elect the peptide containing at least two Lys-Leu-Lys motifs as the species for prosecution. Claims 38-51 and 53-54 read on the elected species

Applicants reserve all rights to reintroduce non-elected species in the event of allowance of a generic claim.

**D. Conclusion**

Applicants believe this paper to be a full and complete response to the Restriction Requirement dated December 7, 2006. Applicants respectfully request favorable consideration of this case in view of the above comments and amendments. Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicants' representative at (512) 536-5654.

Respectfully submitted,



Travis M. Wohlers  
Reg. No. 57,423  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
512.536.3035 (voice)  
512.536.4598 (fax)

Date: June 7, 2007